Opal Wealth Advisors LLC Sells 1,233 Shares of AstraZeneca PLC (NASDAQ:AZN)

Opal Wealth Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN) by 25.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,683 shares of the company’s stock after selling 1,233 shares during the period. Opal Wealth Advisors LLC’s holdings in AstraZeneca were worth $241,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of AZN. McClarren Financial Advisors Inc. grew its stake in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in AstraZeneca in the 3rd quarter worth approximately $28,000. Albion Financial Group UT grew its stake in AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after buying an additional 248 shares in the last quarter. Groupama Asset Managment grew its stake in AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in AstraZeneca in the 3rd quarter worth approximately $45,000. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 0.9 %

NASDAQ:AZN opened at $72.66 on Tuesday. The company has a fifty day moving average of $67.46 and a 200 day moving average of $73.56. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $225.33 billion, a P/E ratio of 32.15, a P/E/G ratio of 1.20 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.55% and a net margin of 13.01%. On average, research analysts predict that AstraZeneca PLC will post 4.66 earnings per share for the current year.

AstraZeneca Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be issued a $1.03 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. This represents a yield of 2%. AstraZeneca’s dividend payout ratio is 43.36%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.